Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
302962-49-8
Molecular formula
C22H26ClN7O2S
Molecular weight
488.01 g/mol
Drug class
Multikinase inhibitorBCR::ABL1 and SRC-family tyrosine kinase inhibitor
Mechanism of action
Inhibits BCR::ABL1 and SRC-family kinases and additional kinases including c-KIT, EPHA2 and PDGFRβ. Inhibition of BCR::ABL1 kinase activity suppresses proliferation and survival of Philadelphia chromosome-positive leukaemic cells.
Indications / reported uses
Treatment of adults with newly diagnosed chronic-phase Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML)
Treatment of adults with chronic, accelerated or blast-phase CML resistant or intolerant to prior therapy, and selected Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) settings
Paediatric Ph+ CML in chronic phase in eligible patients; indications and treatment lines vary by label
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Dasatinib Environmental Risk Assessment (ERA) (the Dasatinib ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.